Favezelimab
- Generic Name
- Favezelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2231068-83-8
- Unique Ingredient Identifier
- H1396W7D1H
- Background
Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06395090
- Locations
- 🇺🇸
Children's Mercy Hospital ( Site 2024), Kansas City, Missouri, United States
🇺🇸Children's Hospital of Philadelphia (CHOP) ( Site 2021), Philadelphia, Pennsylvania, United States
🇨🇳National Taiwan University Hospital ( Site 2983), Taipei, Taiwan
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 174
- Registration Number
- NCT03598608
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center ( Site 0020), Gilbert, Arizona, United States
🇺🇸City of Hope ( Site 0001), Duarte, California, United States
🇺🇸Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007), Los Angeles, California, United States
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
- Conditions
- Interventions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 318
- Registration Number
- NCT03516981
- Locations
- 🇵🇱
Dolnoslaskie Centrum Onkologii. ( Site 0993), Wroclaw, Dolnoslaskie, Poland
🇨🇦Jewish General Hospital ( Site 0307), Montreal, Quebec, Canada
🇺🇸University of California Davis Comprehensive Cancer Center ( Site 0137), Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.